drugset
drugset / Trial / NCT04679909

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

NCT04679909 ↗

Phase 1 Completed 92 enrolled Altimmune, Inc.
RandomizedParallel-groupDouble-blindPrevention

Summary

A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.

Timeline

Start
2021-02-25
Primary completion
2021-12-01
Completion
2022-12-21

Outcome

Missed primary endpoint

release “AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteers” altimmune.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject AdCOVID Unknown — Intranasal

Indications

No indication recorded.